Characterization and selection of Japanese electronic health record databases used as data sources for non-interventional observational studies

Wakabayashi, Yumi; Eitoku, Masamitsu; Suganuma, Narufumi

doi:10.1186/s12911-021-01526-6

Cited by 7 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This observational cohort study analyzed data from the JMDC ® Claims Database in Japan, which includes information on medical claims covered by private health insurance systems since 2005. 11,12 At the time of this study, data were available from 7.2 million salaried workers and their families. Information included inpatient claims (hospitalizations with duration and motive for the hospitalization, tests and procedures performed), outpatient claims (medical visits and diagnoses), and pharmacy claims (dispensed drugs and dates).…”

Section: Methodsmentioning

confidence: 99%

History of Respiratory Events Prior to a First COPD Diagnosis and Future Exacerbations: A Longitudinal Observational Cohort Database Study in Japan

Ding¹,

Zaha²,

Makita³

et al. 2023

COPD

View full text Add to dashboard Cite

Background:Little is known about the association between respiratory events prior to diagnosis of chronic obstructive pulmonary disease (COPD) and future clinical outcomes in Japan. We investigated the association between pre-COPD diagnosis respiratory events and the incidence of exacerbations in a cohort of newly diagnosed COPD patients in Japan. Patients and Methods: Data were retrieved from the JMDC claims database. Patients ≥40 years old with a first COPD diagnosis (≥1 hospitalization or ≥2 outpatient claims for COPD) between 2010 and 2016 were included. The incidence rate (IR) of exacerbations in patients with or without any respiratory event (including lower respiratory tract infection and respiratory failure) in the year preceding diagnosis was compared. A negative binomial model explored the association between pre-diagnosis respiratory event and IR ratio (IRR) of exacerbations. Results: A total of 20,212 patients newly diagnosed with COPD were identified: 61% male, mean age 55 years (SD 9); of these, 955 (4.7%) had experienced ≥1 respiratory event in the year preceding diagnosis. Median duration of follow-up was 3.3 years during which the IR of exacerbations was 0.31 per patient-year (95% confidence interval [CI] 0.29-0.33) in patients with respiratory event, and 0.11 (95% CI 0.10-0.13) in patients without. The IR for severe exacerbation was nearly 10 times greater in patients with respiratory event versus without. Experiencing respiratory event pre-diagnosis was independently associated with an increased IRR of future moderateto-severe exacerbation (adjusted IRR, 2.7; 95% CI 2.3-3.1). Conclusion: Patients experiencing respiratory events in the year preceding COPD diagnosis should be considered at-risk of worse clinical COPD outcomes.

show abstract

Section: Methodsmentioning

confidence: 99%

History of Respiratory Events Prior to a First COPD Diagnosis and Future Exacerbations: A Longitudinal Observational Cohort Database Study in Japan

Ding¹,

Zaha²,

Makita³

et al. 2023

COPD

View full text Add to dashboard Cite

show abstract

“…Moreover, claims‐based algorithms for RA were applied to the commercially available Japan Medical Data Center (JMDC) and Medical Data Vision (MDV) databases, which are among the largest in Japan 20 . Patient demographics and disease characteristics are presented for patients with RA in these databases who met the following criteria: enrollment from January 2005 to May 2019 (JMDC) or April 2008 to October 2019 (MDV); ≥1 definitive diagnosis of RA (excluding suspected cases) with ≥1 RA treatment administered within ±1 month of diagnosis; no diagnosis of psoriasis ±1 month of the RA diagnosis; and aged ≥18 years in the year of the index date (earliest date in which all of the above criteria were satisfied after 12 months from the first record date in the database).…”

Section: Methodsmentioning

confidence: 99%

“…8 Moreover, claims-based algorithms for RA were applied to the commercially available Japan Medical Data Center (JMDC) and Medical Data Vision (MDV) databases, which are among the largest in Japan. 20 Patient demographics and disease characteristics are presented for patients with RA in these databases who met the following criteria: enrollment from January 2005 to May 2019 (JMDC) F I G U R E 1 Study flowchart for the RA cohort. a Claims data did not include personal health information.…”

Section: Validity Measuresmentioning

confidence: 99%

Validation of claims‐based algorithms for rheumatoid arthritis in Japan: Results from the VALIDATE‐J study

Sugiyama,

Kinjo,

Jinno

et al. 2023

Int J of Rheum Dis

View full text Add to dashboard Cite

AimValidity of Algorithms in Large Databases: Infectious Diseases, Rheumatoid Arthritis, and Tumor Evaluation in Japan (VALIDATE‐J) study examined algorithms for identifying rheumatoid arthritis (RA) in Japanese claims data.MethodsVALIDATE‐J was a multicenter, cross‐sectional retrospective study. Disease‐identifying algorithms were used to detect RA diagnosed between January 2012 and December 2016 using claims data from two Japanese hospitals. An RA diagnosis was confirmed using one of four gold standard definitions. Positive predictive values (PPVs) were calculated for prevalent (regardless of baseline RA‐free period) and incident (preceded by a 12‐month RA‐free period) cases.ResultsOf patients identified using claims‐based algorithms, a random sample of 389 prevalent and 134 incident cases of RA were included. Cases identified by an RA diagnosis, no diagnosis of psoriasis, and treatment with any disease‐modifying antirheumatic drugs (DMARDs) resulted in the highest PPVs versus other claims‐based treatment categories (29.0%–88.3% [prevalent] and 41.0%–78.2% [incident]); cases identified by an RA diagnosis, no diagnosis of psoriasis, and glucocorticoid‐only treatment had the lowest PPVs. Across claims‐based algorithms, PPVs were highest when a physician diagnosis or decision by adjudicators (confirmed and probable cases) was used as the gold standard and were lowest when American College of Rheumatology/European Alliance of Associations for Rheumatology 2010 criteria were applied. Positive predictive values of claims‐based algorithms for RA in patients aged ≥66 years were slightly higher versus a USA Medicare population (maximum PPVs of 95.0% and 88.9%, respectively).ConclusionVALIDATE‐J demonstrated high PPVs for most claims‐based algorithms for diagnosis of prevalent and incident RA using Japanese claims data. These findings will help inform appropriate RA definitions for future claims database research in Japan.

show abstract

“…In this regard, a flow diagram was developed allowing users to match a study objective and the data quality and quantity in the Japanese context. The process sequentially clarifies the following elements: construction process (reliability of the data collection), data related to endpoints, anonymization, data volume (sample size), and sufficiency of the follow-up period to address the research question [ 20 ].…”

Section: Challenges and Solutions Relating To Datamentioning

confidence: 99%

Strategies to Address Current Challenges in Real-World Evidence Generation in Japan

Laurent

Lambrelli

Wakabayashi

et al. 2023

Drugs - Real World Outcomes

View full text Add to dashboard Cite

Characterization and selection of Japanese electronic health record databases used as data sources for non-interventional observational studies

Cited by 7 publications

References 29 publications

History of Respiratory Events Prior to a First COPD Diagnosis and Future Exacerbations: A Longitudinal Observational Cohort Database Study in Japan

History of Respiratory Events Prior to a First COPD Diagnosis and Future Exacerbations: A Longitudinal Observational Cohort Database Study in Japan

Validation of claims‐based algorithms for rheumatoid arthritis in Japan: Results from the VALIDATE‐J study

Strategies to Address Current Challenges in Real-World Evidence Generation in Japan

Contact Info

Product

Resources

About